Your Patient Can't Find Their Carbidopa/Levodopa — Here's How to Help

When a Parkinson's patient calls your office to say they can't find their Carbidopa/Levodopa, the clock is ticking. Unlike many chronic medications where a brief gap is inconvenient, interruptions in dopaminergic therapy can precipitate significant motor deterioration, falls, aspiration risk, and in severe cases, a neuroleptic malignant syndrome-like reaction.

This guide provides a practical, step-by-step framework for helping your patients navigate Carbidopa/Levodopa availability issues — from triage to resolution.

Current Availability Overview

Understanding the supply landscape helps you direct patients effectively:

• Immediate-release (IR) tablets — Most available formulation. Multiple manufacturers (Teva, Amneal, Sun Pharma, others) produce 10/100 mg, 25/100 mg, and 25/250 mg strengths. Spot shortages occur but are typically localized and short-lived.
• Extended-release (ER/CR) tablets — Significantly constrained. Accord discontinued the 25/100 mg ER tablet. The 50/200 mg ER remains available but from limited manufacturers.
• Orally disintegrating tablets (ODT) — Reduced availability following manufacturer discontinuations. Particularly impacts patients with dysphagia.
• Rytary and Crexont — Brand-name extended-release capsules. Not in shortage but require prior authorization and are typically specialty pharmacy items.
• Duopa — Enteral suspension for advanced PD. Not affected by the generic shortage; available through specialty channels.

For the detailed shortage timeline and clinical context, see our provider shortage briefing.

Why Patients Can't Find Their Medication

Beyond the supply-side factors, several patient-level barriers contribute to access difficulties:

• Pharmacy loyalty: Most patients use a single pharmacy and don't think to check others when their usual location is out of stock.
• Last-minute refills: Many patients wait until they're on their last day or two of medication before attempting to refill.
• Formulation specificity: Patients on ER or ODT formulations have a smaller pool of available product.
• Insurance and prior authorization delays: Particularly for brand-name formulations, PA processing times can delay access by days.
• The "eight tablet limit": Insurance denials for patients requiring more than 8 tablets daily add another layer of complexity.

What Providers Can Do: 5 Steps

Step 1: Triage the Urgency

When a patient reports they can't find Carbidopa/Levodopa, determine:

• How many days of medication do they have left?
• What formulation and strength are they on?
• Have they tried multiple pharmacies?

If the patient has fewer than 3 days of medication remaining, this is urgent. Carbidopa/Levodopa should not be abruptly discontinued.

Step 2: Direct Patients to Medfinder

Before your staff spends time calling pharmacies, direct patients to Medfinder for Providers. This tool allows patients (or your office staff) to search for real-time pharmacy stock by medication and location.

This single step resolves many access issues — the medication is often available within a reasonable distance, just not at the patient's usual pharmacy.

Step 3: Consider Formulation Flexibility

If the patient's prescribed formulation is genuinely unavailable, consider whether an alternative form of Carbidopa/Levodopa would be appropriate:

• ER → IR conversion: Increase total daily Levodopa by approximately 25-30% and divide into doses every 3-4 hours. This is the most common and usually well-tolerated switch.
• ODT → IR conversion: Generally 1:1 dosing. Patients with dysphagia may need the tablet crushed (IR tablets can be halved but should not be crushed unless needed; consult pharmacist).
• IR → Stalevo: If Entacapone can be added, Stalevo tablets combine Carbidopa/Levodopa/Entacapone and may be available when plain Carbidopa/Levodopa is not.
• IR → Rytary or Crexont: Follow manufacturer conversion tables. Will likely require prior authorization.

Step 4: Write the Prescription Strategically

A few prescribing practices can improve fill rates:

• Allow generic substitution: Write for "Carbidopa/Levodopa" rather than a specific brand to give the pharmacist maximum flexibility.
• Include NDC alternatives: If possible, note that any manufacturer's product is acceptable.
• Prescribe the most available strength: The 25/100 mg IR tablet is the most widely stocked. If clinically appropriate, default to this strength.
• 90-day supply: When the patient finds a pharmacy with stock, prescribe a 90-day supply to reduce refill frequency during the shortage.

Step 5: Proactive Patient Education

Equip your patients before the next shortage hits:

• Advise patients to refill at least 7 days before running out
• Recommend patients establish relationships with 2-3 pharmacies, including at least one independent pharmacy
• Provide patients with Medfinder as a resource to bookmark
• Discuss contingency plans — if Patient can't find ER, they know they can call your office for an IR prescription

Alternative Medications to Consider

When Carbidopa/Levodopa is entirely unavailable, these alternatives may provide temporary or supplementary relief:

• Pramipexole (Mirapex) — Dopamine agonist; may be used alone in early PD or as adjunct. Monitor for impulse control disorders and excessive somnolence, especially in older patients.
• Ropinirole (Requip) — Similar profile to Pramipexole. Extended-release form available for once-daily dosing.
• Rasagiline (Azilect) or Safinamide (Xadago) — MAO-B inhibitors. Can supplement reduced Carbidopa/Levodopa doses. Do not combine with nonselective MAOIs.
• Amantadine — May provide modest symptomatic benefit and can help manage dyskinesia.

For detailed alternative medication information suitable for patients, share our patient guide to Carbidopa/Levodopa alternatives.

Workflow Tips for Your Practice

Integrating shortage management into your practice workflow can reduce last-minute crises:

• Flag shortage-affected patients in your EHR: Identify patients on ER or ODT formulations and proactively reach out to discuss contingency plans.
• Create a shortage protocol: Document your practice's standard approach for converting between formulations, including dose tables and patient handouts.
• Designate a point person: Having one staff member monitor ASHP shortage updates and manage incoming shortage-related patient calls improves efficiency.
• Pre-authorize brand alternatives: For patients on ER formulations, consider submitting prior authorizations for Rytary or Crexont before the shortage hits — having an approved PA in place speeds access when needed.
• Bookmark key resources: Medfinder for Providers, ASHP Drug Shortage Database, and the Parkinson's Foundation Helpline (1-800-4PD-INFO).

Final Thoughts

Carbidopa/Levodopa access issues are a recurring challenge that's unlikely to resolve soon. But with proactive planning, formulation flexibility, and the right tools, you can help ensure your Parkinson's patients maintain continuous access to this essential medication.

The combination of Medfinder for Providers for real-time stock searches, clear conversion protocols for when formulation switches are needed, and patient education about proactive refill practices creates a resilient system that can weather supply disruptions.

For the latest on the Carbidopa/Levodopa supply situation, see our 2026 shortage update. To help patients manage costs, see our provider's guide to helping patients save on Carbidopa/Levodopa.